Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and Safety of Seltorexant as Adjunctive Therapy in Major Depressive Disorder: A Phase 2b, Randomized, Placebo-Controlled, Adaptive Dose-Finding Study
Adam Savitz, Ewa Wajs, Yun Zhang, et al.
The International Journal of Neuropsychopharmacology (2021) Vol. 24, Iss. 12, pp. 965-976
Open Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

Hypocretins (orexins): The ultimate translational neuropeptides
Laura H. Jacobson, Daniël Hoyer, Luı́s de Lecea
Journal of Internal Medicine (2022) Vol. 291, Iss. 5, pp. 533-556
Closed Access | Times Cited: 72
Pharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape
Manish K. Jha, Sanjay J. Mathew
American Journal of Psychiatry (2023) Vol. 180, Iss. 3, pp. 190-199
Closed Access | Times Cited: 58
Clinical specificity profile for novel rapid acting antidepressant drugs
Mauro Scala, Giuseppe Fanelli, Diana De Ronchi, et al.
International Clinical Psychopharmacology (2023) Vol. 38, Iss. 5, pp. 297-328
Open Access | Times Cited: 26
Targeting Orexin Receptors for the Treatment of Insomnia: From Physiological Mechanisms to Current Clinical Evidence and Recommendations
Maria P. Mogavero, Alessandro Silvani, Giuseppe Lanza, et al.
Nature and Science of Sleep (2023) Vol. Volume 15, pp. 17-38
Open Access | Times Cited: 23
Understanding the Biological Relationship between Migraine and Depression
Adrián Viudez‐Martínez, Abraham B. Torregrosa, Francisco Navarrete, et al.
Biomolecules (2024) Vol. 14, Iss. 2, pp. 163-163
Open Access | Times Cited: 9
Discovery and first-time disclosure of CVN766, an exquisitely selective orexin 1 receptor antagonist
Angela Glen, Roland W. Bürli, David G. Livermore, et al.
Bioorganic & Medicinal Chemistry Letters (2024) Vol. 100, pp. 129629-129629
Open Access | Times Cited: 8
Targeting the orexin/hypocretin system for the treatment of neuropsychiatric and neurodegenerative diseases: From animal to clinical studies
Marc Ten-Blanco, África Flores, Luigia Cristino, et al.
Frontiers in Neuroendocrinology (2023) Vol. 69, pp. 101066-101066
Open Access | Times Cited: 19
Emerging and upcoming therapies in insomnia
W.-H. Kim, Ho-Sook Kim
Translational and Clinical Pharmacology (2024) Vol. 32, Iss. 1, pp. 1-1
Open Access | Times Cited: 6
Targeting orexin receptors: Recent advances in the development of subtype selective or dual ligands for the treatment of neuropsychiatric disorders
Alessandro Bonifazi, Fabio Del Bello, Gianfabio Giorgioni, et al.
Medicinal Research Reviews (2023) Vol. 43, Iss. 5, pp. 1607-1667
Closed Access | Times Cited: 13
Aticaprant: (a κ-opioid receptor antagonist) for major depressive disorder
Elliot Hampsey, Luke A. Jelen, Allan H. Young
Expert Opinion on Emerging Drugs (2024) Vol. 29, Iss. 3, pp. 193-204
Open Access | Times Cited: 5
Opportunities for use of neuroimaging in de-risking drug development and improving clinical outcomes in psychiatry: an industry perspective
Amit Etkin, Jessica Powell, Adam Savitz
Neuropsychopharmacology (2024) Vol. 50, Iss. 1, pp. 258-268
Open Access | Times Cited: 5
Emerging Medications for Treatment-Resistant Depression: A Review with Perspective on Mechanisms and Challenges
Michael J. Lucido, Boadie W. Dunlop
Brain Sciences (2025) Vol. 15, Iss. 2, pp. 161-161
Open Access
Efficacy and safety of each class of sleep medication for major depressive disorder with insomnia symptoms: A systematic review and meta‐analysis of double‐blind randomized controlled trials
Taku Maruki, Masahiro Takeshima, Kazuhisa Yoshizawa, et al.
Psychiatry and Clinical Neurosciences (2025)
Open Access
Orexin receptors: possible therapeutic targets for psychiatric disorders
Shigeyuki Chaki
Psychopharmacology (2025)
Closed Access
Investigational Drugs for the Treatment of Depression (Part 1): Monoaminergic, Orexinergic, GABA-Ergic, and Anti-Inflammatory Agents
Octavian Vasiliu
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 21
Lateral hypothalamus orexinergic projection to the medial prefrontal cortex modulates chronic stress-induced anhedonia but not anxiety and despair
Danlei Liu, Xuefeng Zheng, Yuqing Hui, et al.
Translational Psychiatry (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 4
Seltorexant for major depressive disorder
Kyle Valentino, Kayla M. Teopiz, Sabrina Wong, et al.
Expert Opinion on Emerging Drugs (2025)
Closed Access
Orexin Receptor Antagonists in the Treatment of Depression: A Leading Article Summarising Pre-clinical and Clinical Studies
Harry Fagan, Edward G. Jones, David S. Baldwin
CNS Drugs (2022) Vol. 37, Iss. 1, pp. 1-12
Closed Access | Times Cited: 17
Dysregulation of striatal dopamine D2/D3 receptor-mediated by hypocretin induces depressive behaviors in rats
Bing Chen, Jiangang Xu, Simiao Chen, et al.
Journal of Affective Disorders (2023) Vol. 325, pp. 256-263
Closed Access | Times Cited: 8
Characteristics of Seltorexant—Innovative Agent Targeting Orexin System for the Treatment of Depression and Anxiety
Wojciech Ziemichód, Antonina Kurowska, Karolina Grabowska, et al.
Molecules (2023) Vol. 28, Iss. 8, pp. 3575-3575
Open Access | Times Cited: 7
International Union of Basic and Clinical Pharmacology CXIV: Orexin Receptor Function, Nomenclature and Pharmacology
Jyrki P. Kukkonen, Laura H. Jacobson, Daniël Hoyer, et al.
Pharmacological Reviews (2024), pp. PHARMREV-000953
Open Access | Times Cited: 1
Baseline circulating biomarkers, their changes, and subsequent suicidal ideation and depression severity at 6 months: a prospective analysis in patients with mood disorders
Aistė Lengvenytė, Fabrice Cognasse, Hind Hamzeh‐Cognasse, et al.
Psychoneuroendocrinology (2024) Vol. 168, pp. 107119-107119
Open Access | Times Cited: 1
Overview of Psychiatric Medications in the Pipeline in Phase III Trials as of June 1, 2024: A Systematic Review.
Waguih William IsHak, Ashley N. D. Meyer, Luiza Freire, et al.
PubMed (2024) Vol. 21, Iss. 7-9, pp. 27-47
Closed Access | Times Cited: 1
Orexin Receptor Antagonists for the Prevention and Treatment of Alzheimer’s Disease and Associated Sleep Disorders
Matteo Carpi, Nicola Biagio Mercuri, Claudio Liguori
Drugs (2024)
Open Access | Times Cited: 1
Treatment effect and safety of seltorexant as monotherapy for patients with major depressive disorder: a randomized, placebo-controlled clinical trial
Sofie Mesens, Iva Kezic, Peter van der Ark, et al.
Molecular Psychiatry (2024)
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top